Due to the fact that the deactivation of aberrant PI3K signaling in cancer cells, by the activation of SHIP, has been proposed to be a promising approach to treating blood cancers [22,23] (−)-pelorol (1) can be considered as a promoting lead compound for therapeutic development. This evidence concerns the gene INPP5D and cancer.